Skip to content
sellWeak10b5-1 plan

Helen Torley sold $3.9M of HALO

PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 50,000 shares at an average of $77.07, traded Feb 3, 2026, filed Feb 5, 2026.

Warning score
15
Value
$3.9M
50,000 shares
Holdings after
708,719
-7% from before
From 52-week low
+60%
low $47.91, close $76.48
From 52-week high
-2%
high $78.28, as of Feb 3, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $3.9M at market
    +25
  • Share of holdings sold
    Sold 6.9% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HALOOct 9, 2026 · close 110.42
Since filing Feb 5, 2026: +40.8%SPY +15.8% · excess +25.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001159036-26-000012, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 3, 2026MOption exercise
Common Stock10b5-1
+20,000$12.07$241k728,719Feb 5, 2026
Feb 3, 2026SOpen-market sale
Common Stock10b5-1
-2,551$74.88$191k726,168Feb 5, 2026
Feb 3, 2026SOpen-market sale
Common Stock10b5-1
-9,659$75.94$734k716,509Feb 5, 2026
Feb 3, 2026SOpen-market sale
Common Stock10b5-1
-7,790$76.73$598k708,719Feb 5, 2026
Feb 4, 2026MOption exercise
Common Stock10b5-1
+20,000$12.07$241k728,719Feb 5, 2026
Feb 4, 2026SOpen-market sale
Common Stock10b5-1
-9,900$76.94$762k718,819Feb 5, 2026
Feb 4, 2026SOpen-market sale
Common Stock10b5-1
-10,100$77.54$783k708,719Feb 5, 2026
Feb 5, 2026MOption exercise
Common Stock10b5-1
+10,000$12.07$121k718,719Feb 5, 2026
Feb 5, 2026SOpen-market sale
Common Stock10b5-1
-5,376$78.38$421k713,343Feb 5, 2026
Feb 5, 2026SOpen-market sale
Common Stock10b5-1
-4,624$78.94$365k708,719Feb 5, 2026
Feb 3, 2026MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$12.07$241k231,923Feb 5, 2026
Feb 4, 2026MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$12.07$241k211,923Feb 5, 2026
Feb 5, 2026MOption exercise
Option to Purchase Common Stockderivative10b5-1
-10,000$12.07$121k201,923Feb 5, 2026

Related signals

Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.6M
60,000 shares
-8%
22Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$568k
5,230 shares
-9%
33Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$2.0M
18,996 shares
-24%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.4M
60,000 shares
-8%
58Moderate
HALOsell 2
HALOZYME THERAPEUTICS, INC.
Cortney Caudill
SVP, CHIEF OPERATING OFFICER
$2.0M
28,857 shares
-84%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.5M
50,000 shares
-6%
6Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$141k
2,000 shares
-5%
44Moderate
HALOsell 3
HALOZYME THERAPEUTICS, INC.
Cortney Caudill
SVP, CHIEF OPERATING OFFICER
$278k
4,263 shares
-25%
10Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$59k
829 shares
-2%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$1.1M
16,569 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.